FDA Awards Experimental Anti-Ebola Drug ZMapp Fast-Tracking Status - NBC4 Washington

FDA Awards Experimental Anti-Ebola Drug ZMapp Fast-Tracking Status

    processing...

    NEWSLETTERS

    Celebrating Life After Breast Cancer
    Getty Images

    ZMapp, an experimental drug being tested against Ebola, has won fast-track status to get quicker Food and Drug Administration approval, NBC News reported.

    The drug, which made headlines when some high-profile American Ebola patients tried it out, is still being tested in Liberia, where there haven't been any new cases of Ebola reported in months.

    ZMapp is best known as the drug given to the first U.S. Ebola patient, Dr. Kent Brantly — the medical missionary air-evacuated from Liberia for treatment in the U.S.

    Brantly survived, but doctors say they don't know whether ZMapp helped.